Sustained and rebound effect of repeated low-level red-light therapy on myopia control: A 2-year post-trial follow-up study
Xiong R, Zhu Z, Jiang Y, Kong X, Zhang J, Wang W, Kiburg K, Yuan Y, Chen Y, Zhang S, Xuan M, Zeng J, Morgan IG, He M
Clinical & experimental ophthalmology · 115 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- University of Melbourne
- Gobierno
- National Natural Science Foundation of China
- Universidad u hospital
- State Key Laboratory of Ophthalmology
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- National Natural Science Foundation of China (81271037); State Key Laboratory of Ophthalmology (303060202400362); National Natural Science Foundation of China (81420108008)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-08-25 · Clin Exp Ophthalmol · vol. 50 · número 9 · págs. 1013–1024
- Editorial
- Wiley
- Citado
- 133 citas · más que el 100% de estudios similares · 15.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Laser Applications in Dentistry and Medicine
- Palabras clave
- Medicine, Randomized controlled trial, Ophthalmology, Light therapy, Repeated measures design, Surgery, Internal medicine, Circadian rhythm
- MeSH
- humans, myopia, disease progression, refraction, ocular, phototherapy, follow-up studies, eyeglasses, child, axial length, eye
14 autores
- Ruilin Xiong🇨🇳Sun Yat-sen University
- Zhuoting Zhu🇨🇳🇦🇺Sun Yat-sen University; The University of Melbourne; Centre for Eye Research Australia
- Yu Jiang🇨🇳Sun Yat-sen University
- Xiangbin Kong🇨🇳Foshan Maternity and Child Health Care Hospital; Southern Medical University
- Jian Zhang🇨🇳Sun Yat-sen University
- Wei Wang🇨🇳Sun Yat-sen University
- Katerina Kiburg🇦🇺Centre for Eye Research Australia
- Yixiong Yuan🇨🇳Sun Yat-sen University
- Yanping Chen🇨🇳Sun Yat-sen University
- Shiran Zhang🇨🇳Sun Yat-sen University
- Meng Xuan🇨🇳Sun Yat-sen University
- Junwen Zeng🇨🇳Sun Yat-sen University
- Ian George Morgan🇦🇺Australian National University
- Mingguang He🇨🇳🇦🇺 · autor de correspondenciaSun Yat-sen University; The University of Melbourne; Centre for Eye Research Australia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
To evaluate the long-term efficacy and safety of continued repeated low-level red-light (RLRL) therapy on myopia control over 2 years, and the potential rebound effect after treatment cessation.
Methods
The Chinese myopic children who originally completed the one-year randomised controlled trial were enrolled. Children continued RLRL-therapy were defined as RLRL-RLRL group, while those who stopped and switched to single-vision spectacle (SVS) in the second year were RLRL-SVS group. Likewise, those who continued to merely wear SVS or received additional RLRL-therapy were SVS-SVS and SVS-RLRL groups, respectively. RLRL-therapy was provided by an at-home desktop light device emitting red-light of 650 nm and was administered for 3 min at a time, twice a day and 5 days per week. Changes in axial length (AL) and cycloplegic spherical equivalence refraction (SER) were measured.
Results
Among the 199 children who were eligible, 138 (69.3%) children attended the examination and 114 (57.3%) were analysed (SVS-SVS: n = 41; SVS-RLRL: n = 10; RLRL-SVS: n = 52; RLRL-RLRL: n = 11). The baseline characteristics were balanced among four groups. In the second year, the mean changes in AL were 0.28 ± 0.14 mm, 0.05 ± 0.24 mm, 0.42 ± 0.20 mm and 0.12 ± 0.16 mm in SVS-SVS, SVS-RLRL, RLRL-SVS and RLRL-RLRL group, respectively (p < 0.001). The respective mean SER changes were -0.54 ± 0.39D, -0.09 ± 0.55D, -0.91 ± 0.48D, and -0.20 ± 0.56D (p < 0.001). Over the 2-year period, axial elongation and SER progression were smallest in RLRL-RLRL group (AL: 0.16 ± 0.37 mm; SER: -0.31 ± 0.79D), followed by SVS-RLRL (AL: 0.44 ± 0.37 mm; SER: -0.96 ± 0.70D), RLRL-SVS (AL: 0.50 ± 0.28 mm; SER: -1.07 ± 0.69D) and SVS-SVS group (AL: 0.64 ± 0.29 mm; SER: -1.24 ± 0.63D). No self-reported adverse events, functional or structural damages were noted.
Conclusions
Continued RLRL therapy sustained promising efficacy and safety in slowing myopia progression over 2 years. A modest rebound effect was noted after treatment cessation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.